A5073757908- Diabetes Management and Research
- Diabetes Treatment and Management
- Medication Adherence and Compliance
- Diabetes and associated disorders
- Pancreatic function and diabetes
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Mobile Health and mHealth Applications
- Blood Pressure and Hypertension Studies
- Diabetes Management and Education
- Pharmaceutical Practices and Patient Outcomes
- Bipolar Disorder and Treatment
- Hepatitis C virus research
- Diet and metabolism studies
- Spectroscopy Techniques in Biomedical and Chemical Research
- Artificial Intelligence in Healthcare
- Respiratory and Cough-Related Research
- Pharmaceutical Economics and Policy
- Pneumonia and Respiratory Infections
- Big Data and Business Intelligence
- Cardiac Health and Mental Health
- Bacterial Infections and Vaccines
- Health Systems, Economic Evaluations, Quality of Life
- Artificial Intelligence in Healthcare and Education
Diabetes Care Center
2021-2025
Abbott Diabetes Care (United States)
2021-2025
Manitoba Beekeepers' Association
2019
Abbott (United States)
2019
College of Alameda
2019
Proteus Digital Health
2015-2018
Background: Hypertension and type 2 diabetes mellitus are major modifiable risk factors for cardiac, cerebrovascular, kidney diseases. Reasons poor disease control include nonadherence, lack of patient engagement, therapeutic inertia.
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) therapy provides glycemic benefits to individuals with type 2 diabetes (T2D). However, the effects of GLP-1 RA in combination FreeStyle Libre systems (FSL) are unknown. This study aimed compare changes hemoglobin A1c (HbA1c) between people acquiring FSL (GLP-1+FSL) versus without (GLP-1).
Background: The clinical significance of blood glucose meter (BGM) error in the presence increasing carbohydrate errors diabetes patients who use both BGM result and estimation to dose insulin is unknown. Methods: This Monte Carlo simulation modeled calculate dosages based on results estimations. It evaluated likelihood on-target dosing clinically significant data from five BGMs with different levels performance (expressed as bias imprecision [coefficient variation (%CV)]) errors. study was...
Background: The value of self-monitoring blood glucose (SMBG) for persons with type 2 diabetes who do not use insulin remains controversial. This observational study compares the likelihood medication adherence and change in glycated hemoglobin (A1C) non–insulin-using patients using SMBG versus those SMBG. also assessed association between use. Patients Methods: Data were extracted on 5,172 began non-insulin October 1, 2006, March 31, 2009. A1C associated testing frequency at different...
Objective: We assessed the economic impact of using newest flash continuous glucose monitoring (CGM) among Medicaid beneficiaries with diabetes treated intensive insulin therapy (IIT). Research Design and Methods: A budget analysis was created to assess increasing proportion on IIT, who use CGM by 10%. The included device costs, cost savings due reductions in glycated hemoglobin, severe hypoglycemia events, hyperglycemic emergencies such as diabetic ketoacidosis. net change costs per person...
Both glucagon-like peptide-1 receptor agonists (GLP-1 RA) and continuous glucose monitoring (CGM) improve glycemia in patients with type 2 diabetes (T2D). However, it is unknown whether adding CGM to GLP-1 RA therapy further improves A1c. We evaluated changes A1c levels 6 months after initiation of FreeStyle Libre (FSL) adults sub-optimally controlled T2D already on therapy.
Background: Clinical trials have shown that self-monitoring of blood glucose (SMBG) combined with patient education and medication titration can lead to improved glycated hemoglobin (HbA1c) reduced weight in recently diagnosed non-insulin-treated type 2 diabetes mellitus (T2DM) patients. This retrospective matched cohort study assessed the association SMBG achieving long-term clinical outcomes these patients a real-world setting. Methods: Using electronic medical records (2008–2011), we...
Background: We evaluated the association between self-monitoring of blood glucose (SMBG) use and sitagliptin or sitagliptin/ metformin (SSMT) adherence. SSMT was chosen as these medications have little risk hypoglycemia are believed to not require SMBG data for titration. Methods: This an observational study using extracted from a large United States insurance claims database (i3 InVision™ Data Mart, Ingenix, Inc.). were on noninsulin-using patients initiating each 12-month period pre-...
We compared clinical outcomes after acquiring a FreeStyle Libre© Flash Continuous Glucose Monitoring System (FSL) or Dexcom (DEX) continuous glucose monitoring (CGM) device in individuals with type 1 diabetes (T1D) and 2 (T2D) treated intensive insulin therapy.
The increasing prevalence of diabetes in the United States continues to drive a steady rise health care resource utilization, especially emergency department visits and all-cause hospitalizations, associated costs.
Global data from real world use of flash glucose monitoring have correlated higher frequency scanning with better glycemic control. Because became available in late 2017 the United States, U.S. was not captured early global analysis. The objective this study highlight outcomes patients using A server collected deidentified who uploaded their system readers. Data within were analyzed through September 2018. Individuals divided into 10 equal sized groups based on frequency. Average time range...